News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
PPD has added several new hires across multiple therapeutic areas, including neuroscience, oncology, rare diseases, and pediatrics.
“As the drug development process continues to become more complex, our clients are looking to PPD to provide medical and scientific expertise and strategic direction that extend far beyond traditional clinical trial implementation,” said Rob Dow, PPD chief medical officer.
Dow told us the new hires have held senior leadership roles in various capacities in the life sciences industry, providing them with a range of experience that offers “significant strategic value” to clients.
“In their new positions, they will help develop cross-functional integrated product development plans and assist with the design of clinical trials that include relevant indication-specific endpoints and the use of traditional and novel statistical approaches,” he added.
“An important role for our therapeutic area experts is to assist our clients in anticipating and overcoming clinical and regulatory challenges in product development, saving time and enabling the achievement of timely, cost-effective and informed decisions.”
Among the new hires includes Amy Chappell, MD, who worked with Eli Lilly and Company for 25 years before transitioning to a consultant for companies such as Convergence Pharma, Biogen, Advicenne, Flexion, and Lundbeck.
Chappell is board certified in neurology and lifestyle medicine, and has authored or co-authored more than 75 scientific publications and presentations.